» Articles » PMID: 34217318

Multi-trajectories of Lipid Indices with Incident Cardiovascular Disease, Heart Failure, and All-cause Mortality: 23 years Follow-up of Two US Cohort Studies

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2021 Jul 4
PMID 34217318
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Understanding the distinct patterns (trajectories) of variation in blood lipid levels before diagnosing cardiovascular disease (CVD) might carry important implications for improving disease prevention or treatment.

Methods: We investigated 14,373 participants (45.5% men) aged 45-84 from two large US prospective cohort studies with a median of 23 years follow-up. First, we jointly estimated developmental trajectories of lipid indices, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) concentrations using group-based multi-trajectory modeling. Then, the association of identified multi-trajectories with incident CVD, heart failure, and all-cause mortality were examined using Cox proportional hazard model.

Results: Seven distinct multi-trajectories were identified. The majority of participants (approximately 80%) exhibited decreasing LDL-C but rising TG levels and relatively stable HDL-C levels. Compared to the individuals with healthy and stable LDL-C, HDL-C, and TG levels, those in other groups were at significant risk of incident CVD after adjusting for other conventional risk factors. Individuals with the highest but decreasing LDL-C and borderline high and rising TG levels over time were at the highest risk than those in other groups with a 2.22-fold risk of CVD. Also, those with the highest and increased triglyceride levels over time, over optimal and decreasing LDL-C levels, and the lowest HDL-C profile had a nearly 1.84 times CVD risk. Even individuals in the multi-trajectory group with the highest HDL-C, optimal LDL-C, and optimal TG levels had a significant risk (HR, 1.45; 95% CI 1.02-2.08). Furthermore, only those with the highest HDL-C profile increased the risk of heart failure by 1.5-fold (95% CI 1.07-2.06).

Conclusions: The trajectories and risk of CVD identified in this study demonstrated that despite a decline in LDL-C over time, a significant amount of residual risk for CVD remains. These findings suggest the impact of the increasing trend of TG on CVD risk and emphasize the importance of assessing the lipid levels at each visit and undertaking potential interventions that lower triglyceride concentrations to reduce the residual risk of CVD, even among those with the optimal LDL-C level.

Citing Articles

Mendelian randomization of plasma lipidome, inflammatory proteome and heart failure.

Zheng Z, Tan X ESC Heart Fail. 2024; 11(6):4209-4221.

PMID: 39145416 PMC: 11631237. DOI: 10.1002/ehf2.14997.


SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study.

Li J, Li C, Feng X, Wei X ESC Heart Fail. 2024; 11(6):3960-3971.

PMID: 39054757 PMC: 11631244. DOI: 10.1002/ehf2.14987.


Combined blood pressure and heart rate trajectories are associated with prognosis in critically ill patients with acute aortic dissection: A group-based multi-trajectory analysis.

Shen X, Li J, Yan H, Zhou S, Yang S, Li W Heliyon. 2024; 10(9):e29934.

PMID: 38707356 PMC: 11066306. DOI: 10.1016/j.heliyon.2024.e29934.


Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies.

Koohi F, Khalili D, Soori H, Nazemipour M, Mansournia M Glob Epidemiol. 2023; 4:100075.

PMID: 37637024 PMC: 10445971. DOI: 10.1016/j.gloepi.2022.100075.


Lipid Levels During Adult Lifetime in Men and Women With and Without a Subsequent Incident Myocardial Infarction: A Longitudinal Analysis of Data From the Tromsø Study 1974 to 2016.

Albrektsen G, Wilsgaard T, Heuch I, Lochen M, Thelle D, Njolstad I J Am Heart Assoc. 2023; 12(14):e030010.

PMID: 37449584 PMC: 10382082. DOI: 10.1161/JAHA.122.030010.


References
1.
Madsen C, Varbo A, Nordestgaard B . Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017; 38(32):2478-2486. DOI: 10.1093/eurheartj/ehx163. View

2.
Ganda O, Bhatt D, Mason R, Miller M, Boden W . Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol. 2018; 72(3):330-343. DOI: 10.1016/j.jacc.2018.04.061. View

3.
Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

4.
Bild D, Bluemke D, Burke G, Detrano R, Diez Roux A, Folsom A . Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-81. DOI: 10.1093/aje/kwf113. View

5.
Jorgensen A, Frikke-Schmidt R, West A, Grande P, Nordestgaard B, Tybjaerg-Hansen A . Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2012; 34(24):1826-33. DOI: 10.1093/eurheartj/ehs431. View